AMENDED AND RESTATED SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 1st, 2020 • Rexahn Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJuly 1st, 2020 Company Industry JurisdictionAMENDED AND RESTATED SECURITIES PURCHASE AGREEMENT (this "Agreement"), dated as of June 29, 2020 (the "Amendment and Restatement Date"), by and among Ocuphire Pharma, Inc., a Delaware corporation, with headquarters located at 37000 Grand River Ave, Suite 120, Farmington Hills, MI 48335 ("Ocuphire"), Rexahn Pharmaceuticals, Inc., a Delaware corporation, with headquarters located at 15245 Shady Grove Road, Suite 455, Rockville, MD 20850 ("Rexahn"), and the investors listed on the Schedule of Buyers attached hereto (each, a "Buyer" and collectively, the "Buyers").
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 19th, 2020 • Rexahn Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJune 19th, 2020 Company Industry JurisdictionSECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of June 17, 2020, by and among Ocuphire Pharma, Inc., a Delaware corporation, with headquarters located at 37000 Grand River Ave, Suite 120, Farmington Hills, MI 48335 (“Ocuphire”), Rexahn Pharmaceuticals, Inc., a Delaware corporation, with headquarters located at 15245 Shady Grove Road, Suite 455, Rockville, MD 20850 (“Rexahn”), and the investors listed on the Schedule of Buyers attached hereto (each, a “Buyer” and collectively, the “Buyers”).